Both preclinical and clinical evidence indicates that, upon crossing the BBB, adiponectin can modulate synaptic plasticity, neurogenesis, and neuronal survival, processes central to the pathophysiology of depressive disorders. Here, ADIPOQ is linked to depressive disorder.